Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of tirzepatide. Weekly tirzepatide injections significantly ...

In the SURMOUNT-1 trial, obese patients without diabetes who received tirzepatide with monthly lifestyle counseling lost 20.9% of baseline weight at 72 weeks (versus 3.1% for placebo) with ...

The results from a sub-population of patients in Lilly's SURMOUNT-1 trial suggest that tirzepatide could provide an alternative that, at least in theory, could require less dramatic lifestyle changes.

The authors examined the percent change in body weight from randomization to week 72 (SURMOUNT-1, -2, and -3) or week 52 (SURMOUNT-4), as well as the proportions of participants achieving the ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

31.6% of people taking Zepbound achieved at least 25% body weight loss compared to 16.1% of those taking Wegovy. The overall safety profile of Zepbound in SURMOUNT-5 was similar to previously ...

Lilly intends to continue to evaluate the SURMOUNT-5 results, which will be published in a peer-reviewed journal and presented at a medical meeting next year. 1 "Given the increased interest around ...

Surmount AI specializes in helping individual ... you know, a tune of, like, 1,000x,” he said. Weaver emphasized that AI is rapidly catching up in finance, an industry that had been slower ...